The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN- amplified neuroblastoma
Science Advances · 31.05.2024 · 10 (22)
DOI: 10.1126/sciadv.adm9449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 31.05.2024. Verfasst von Clare F Malone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Gene Expression Regulation, Neoplastic, N-Myc Proto-Oncogene Protein, Neuroblastoma, Lysine Acetyltransferases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Pediatric cancers are frequently driven by genomic alterations that result in aberrant transcription factor activity. Here, we used functional genomic screens to identify multiple genes within the transcriptional coactivator Spt-Ada-Gcn5-acetyltransferase (SAGA) complex as selective dependencies for MYCN -amplified neuroblastoma, a disease of dysregulated development driven by an aberrant oncogenic transcriptional program. We characterized the DNA recruitment sites of the SAGA complex in neuroblastoma and the consequences of loss of SAGA complex lysine acetyltransferase (KAT) activity on histone acetylation and gene expression. We demonstrate that loss of SAGA complex KAT activity is associated with reduced MYCN binding on chromatin, suppression of MYC/MYCN gene expression programs, and impaired cell cycle progression. Further, we showed that the SAGA complex is pharmacologically targetable in vitro and in vivo with a KAT2A/KAT2B proteolysis targeting chimeric. Our findings expand our understanding of the histone-modifying complexes that maintain the oncogenic transcriptional state in this disease and suggest therapeutic potential for inhibitors of SAGA KAT activity in MYCN -amplified neuroblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- The Center for Cancer Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
ORCID-Profile: Clare F Malone, Nathaniel W Mabe, Alexandra B Forman, Gabriela Alexe, Kathleen L Engel, Ying-Jiun C Chen, Melinda Soeung, Sharon Y R Dent, Kimberly Stegmaier
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Malone, C. F., Mabe, N. W., Forman, A. B., Alexe, G., Engel, K. L., Chen, Y. C., Soeung, M., Salhotra, S., Basanthakumar, A., Liu, B., Dent, S. Y. R., & Stegmaier, K. (2024). The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN- amplified neuroblastoma. Science Advances, 10(22). https://doi.org/10.1126/sciadv.adm9449
Vancouver
Malone CF, Mabe NW, Forman AB, Alexe G, Engel KL, Chen YC, et al. The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN- amplified neuroblastoma. Science Advances. 2024;10(22). doi:10.1126/sciadv.adm9449
BibTeX
@article{Malone2024,
author = {Malone, Clare F and Mabe, Nathaniel W and Forman, Alexandra B and Alexe, Gabriela and Engel, Kathleen L and Chen, Ying-Jiun C and Soeung, Melinda and Salhotra, Silvi and Basanthakumar, Allen and Liu, Bin and Dent, Sharon Y R and Stegmaier, Kimberly},
title = {The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN- amplified neuroblastoma},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {22},
doi = {10.1126/sciadv.adm9449}
}
EUVIMED